Evaluation of Ki67 staining revealed that residual tumor cells in MRLs at either 28 days or 56 days following HER2/neu downregulation exhibited rates of Ki67 positivity more than 40-fold lower than primary tumor cells (Fig. 2a, d). This evidence concerns the gene ERBB2 and neoplasm.